Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine

Lawrence M. Gelbert(Eli Lilly (United States)), Alfonso de Dios(Eli Lilly (United States))

Investigational New Drugs

June 12, 2014

10.1007/s10637-014-0120-7

Cited by 564

Related Papers

Identification and characterization of the familial adenomatous polyposis coli gene

|Cell|1991|2.8k

Identification of deletion mutations and three new genes at the familial polyposis locus

|Cell|1991|768

Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer

|Cancer Research|2024|19